Home › Funds › STEMPOINT CAPITAL LP › AMLX
STEMPOINT CAPITAL LP position in AMLX
AMYLYX PHARMACEUTICALS INC · Health Care
STEMPOINT CAPITAL LP reported holding 384,304 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$6.9M, representing 1.53% of its reported portfolio and ranking #22 among its reported holdings. STEMPOINT CAPITAL LP has disclosed AMLX holdings in 5 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How STEMPOINT CAPITAL LP's AMLX position evolved
STEMPOINT CAPITAL LP first disclosed a stake in AMLX in Q4 2023 at 83,381 shares (US$1.2M). The position peaked in Q1 2026 at 669,685 shares, worth US$9.3M. Across 5 filings, STEMPOINT CAPITAL LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 384,304 shares valued at US$6.9M — a reduction of -285,381 shares quarter over quarter.. Notable position changes include a 104% increase in Q4 2025 (shares rose 15% over the following quarter), a 43% trim in Q2 2026 (shares rose 62% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 83.38K | $1.23M | New |
| Q3 2025 | 276.88K | $3.76M | New |
| Q4 2025 | 565.14K | $6.83M | Add |
| Q1 2026 | 669.68K | $9.31M | Add |
| Q2 2026 | 384.30K | $6.90M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMLX and 13F data
AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 50 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$149.7M), TCG Crossover Management, LLC (US$112.1M), Commodore Capital LP (US$101.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMLX
- PERCEPTIVE ADVISORS LLC 8.33M sh · $149.69M · Q2 2026
- TCG Crossover Management, LLC 6.24M sh · $112.14M · Q2 2026
- Commodore Capital LP 5.65M sh · $101.47M · Q2 2026
- Saturn V Capital Management LP 4.62M sh · $83.05M · Q2 2026
- First Light Asset Management, LLC 3.02M sh · $54.30M · Q2 2026
- Siren, L.L.C. 1.48M sh · $26.59M · Q2 2026
- Almitas Capital LLC 974.88K sh · $17.51M · Q2 2026
- Jones Hill Capital LP 894.06K sh · $16.06M · Q2 2026
- Boxer Capital Management, LLC 800.00K sh · $14.37M · Q2 2026
- GREAT POINT PARTNERS LLC 700.00K sh · $12.57M · Q2 2026
- Parkman Healthcare Partners LLC 398.78K sh · $7.16M · Q2 2026
- HighVista Strategies LLC 386.08K sh · $6.93M · Q2 2026
More on STEMPOINT CAPITAL LP
FAQ
How long has STEMPOINT CAPITAL LP held AMLX?
STEMPOINT CAPITAL LP has disclosed AMLX holdings in 5 of the last 11 reported quarters, going back to Q4 2023.
What is STEMPOINT CAPITAL LP's current position in AMLX?
As of Q2 2026, STEMPOINT CAPITAL LP holds 384.30K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $6.90M, representing 1.53% of its reported portfolio and ranking #22.
Has STEMPOINT CAPITAL LP been buying or selling AMLX?
In the latest 13F filing (Q2 2026), STEMPOINT CAPITAL LP reduced its position in AMLX. The position peaked in Q1 2026 at 669.68K shares.
Which other funds hold AMLX?
Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, Commodore Capital LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.